Previous article
Related Articles
The Pharmaceutical Accountability Foundation faces AbbVie in Court for the first time in its Humira pricing case
AMSTERDAM, THE NETHERLANDS: In February of 2023, the Pharmaceutical Accountability Foundation (PAF) brought a lawsuit against the company on the grounds that AbbVie had...
“Six billion people have access to medicines today. So a lot has been achieved”
Wilbert Bannenberg, Chair of the Pharmaceutical Accountability Foundation, was interviewed by the Volkskrant on his life's work: promoting global equitable access to medicines. The...
AbbVie tries to escape accountability for overcharging the Dutch healthcare system by 1.2 billion Euros
AMSTERDAM, THE NETHERLANDS: In February of 2023, the Pharmaceutical Accountability Foundation (PAF) brought a lawsuit against the company on the grounds that AbbVie had...
The Pharmaceutical Accountability Foundation’s case against AbbVie: The Facts
Version 15 November 2023
About Adalimumab/Humira and pricing issues
AbbVie’s blockbuster drug Adalimumab (brand name: Humira) for the treatment of rheumatoid arthritis is one of the...